^
Association details:
| Biomarker: | PRDM1 mutation |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | imatinib (Bcr-abl inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Prevalence of monoclonal gammopathy of uncertain significance in chronic myeloid leukemia: A case report
Published date:
11/02/2018
Excerpt:
A 52-year-old female was diagnosed with CML in April 2001….Missense mutation in PRDM1 was identified….Because of her obvious decrease of platelets, she started treatment with thalidomide (200 mg/day) and prednisone (50 mg/day), and at the same time imatinib treatment was continued....Three months later, bone marrow aspirate showed disappearance of plasma cells....
Secondary therapy:
prednisone + thalidomide
DOI:
10.1097/MD.0000000000013103